TIDMHIK 
 
RNS Number : 6686T 
Hikma Pharmaceuticals Plc 
01 October 2010 
 

Hikma reiterates its guidance of at least 20% revenue growth for its US Generics 
business in 2010 
 
 
London, 1 October 2010 - Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ DUBAI: 
HIK)("Hikma"), the fast growing multinational pharmaceutical group, notes recent 
press speculation that the United States Food and Drug Administration intends to 
take enforcement action against unapproved single-ingredient oral colchicine 
products and those companies that manufacture and sell them. 
 
Hikma can confirm that it will comply with any FDA regulatory requirements 
related to the sale of colchicine, if such a notice is served.  Irrespective of 
the timing of such notification, Hikma is confident in reiterating its guidance 
of at least 20% revenue growth for its US Generics business for the full year 
2010 and expects its core US Generics business will continue to perform well in 
2011. 
 
 
                                      ENDS 
 
 
+-----------------------------------+-----------------------------------+ 
| Enquiries                         |                                   | 
+-----------------------------------+-----------------------------------+ 
| Hikma Pharmaceuticals PLC         | +44 (0)20 7399 2760               | 
+-----------------------------------+-----------------------------------+ 
| Susan Ringdal, Investor Relations |                                   | 
| Director                          |                                   | 
+-----------------------------------+-----------------------------------+ 
|                                   |                                   | 
+-----------------------------------+-----------------------------------+ 
| Financial Dynamics                |                                   | 
+-----------------------------------+-----------------------------------+ 
| Ben Atwell                        | +44 (0)20 7269 7242               | 
+-----------------------------------+-----------------------------------+ 
| Julia Phillips                    | +44 (0)20 7269 7187               | 
+-----------------------------------+-----------------------------------+ 
| Matthew Cole                      |                                   | 
+-----------------------------------+-----------------------------------+ 
 
 
About Hikma 
Hikma Pharmaceuticals PLC is a fast growing global pharmaceutical group focused 
on developing, manufacturing and marketing a broad range of both branded and 
non-branded generic and in-licensed products.  Hikma's operations are conducted 
through three businesses: "Branded", "Injectables" and "Generics" based 
primarily in the Middle East and North Africa ("MENA") region, where it is a 
market leader, the United States and Europe.  In 2009, Hikma achieved revenues 
of  $637 million and profit attributable to shareholders of $78 million.  For 
news and other information, please visit www.hikma.com. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCLFFSVAVIIVII
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.